Following Christopher Brett Primiano’s last KPTI Sell transaction on November 09, 2017, the stock climbed by 5.3%. In addition to Christopher Brett Primiano, 4 other KPTI executives reported Sell trades in the last month.
Based on Karyopharm Therapeutics’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $18.1 million and GAAP net loss of $48.65 million. In comparison, last year the company earned revenue of $206K and had a GAAP net loss of $58.21 million. The company has a one-year high of $20.09 and a one-year low of $3.92. The Company has a Price to Book ratio of 16.8520.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.